➡ Interstitial lung disease (ILD) is an umbrella term used for a large group of diseases that cause irreversible fibrosis of the lungs. In many cases, such as idiopathic pulmonary fibrosis (IPF), the causes may be unknown.
➡ There is currently no cure for IPF. Pirfenidone and nintedanib are used with the aim of relieving the symptoms as much as possible and slowing down its progression. Bot drugs, however, cause significant unwanted side effects when given orally.
➡ Inhalation therapy could potentially increase the local drug concentration while simultaneously decrease systemic exposure. This presentation will explore if it is possible and meaningful to deliver drug aerosols to fibrotic lungs.
➡ Emerging technologies and innovations in inhalation therapy
➡ Challenges in developing inhalation therapy for different respiratory conditions
➡ Regulatory considerations for inhalation therapy products
➡ Patient-centered approach in inhalation therapy development
➡ Sustainability and environmental impact of inhalation therapy devices
➡ The role of digital health in improving inhalation therapy outcomes
20-21 June 2023 @World of Wine Porto, Portugal